
ALXO Stock Forecast & Price Target
ALXO Analyst Ratings
Bulls say
ALX Oncology Holdings Inc exhibits a promising financial outlook, with projected initial revenue of $45 million in 2032, escalating to $278 million by 2034. The company has successfully extended its cash runway into the fourth quarter of 2026, facilitating focused development on its breast and colorectal cancer programs, where the mechanism of action for the lead candidate, evorpacept, has been clinically de-risked. This strategic positioning not only enhances operational efficiency but also underscores the potential for significant revenue growth as the clinical trials advance.
Bears say
ALX Oncology Holdings reported no revenues for 1Q25, aligning with consensus estimates, but posted a higher net loss of $0.58 per share, exceeding the anticipated net loss of $0.47 per share. The company has also made the strategic decision to discontinue the evaluation of its product candidate, Evo, in head and neck squamous cell carcinoma (HNSCC) and bladder cancer due to underwhelming clinical data results. Furthermore, the FDA's request for a Phase 3 study using Enhertu as a control, citing insufficient data from the Phase 2 ASPEN-06 study for accelerated approval, raises concerns about the viability of ALX’s leading product candidate and its future revenue potential.
This aggregate rating is based on analysts' research of ALX Onconology Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ALXO Analyst Forecast & Price Prediction
Start investing in ALXO
Order type
Buy in
Order amount
Est. shares
0 shares